Immunohistochemical analysis in tumors after 11, 18, and 30 days of therapy with C225 and gemcitabine
| Therapy | VEGFa expression Average (SD) | IL-8a expression Average (SD) | MVDb Median (range) | % apoptotic EC/Total ECc Median (range) |
|---|---|---|---|---|
| Control | ||||
| 11 days | 172 (28) | 170 (28) | 37 (30–54) | 0 (0–12) |
| 18 days | 220 (26) | 191 (17) | 73 (53–90) | 0 (0–5) |
| 30 days | 151 (20) | 202 (32) | 56 (24–180) | 0 (0–6) |
| Gemcitabine | ||||
| 11 days | 162 (21)d | 168 (21)d | 38 (31–64)d | 0 (0–15)d |
| 18 days | 150 (21)d | 210 (35)d | 69 (51–72)d | 0 (0–5)d |
| 30 days | 165 (33)d | 204 (48)d | 78 (60–89)d | 10 (7–26)e |
| C225 | ||||
| 11 days | 97 (13)e | 100 (13)f | 27 (15–34)e | 19 (0–40)e |
| 18 days | 98 (13)e | 94 (14)f | 16 (14–44)f | 69 (60–81)f |
| 30 days | 110 (2)e | 113 (20)f | 19 (16–22)e | 63 (60–67)f |
| C225+ gemcitabine | ||||
| 11 days | 109 (9)e | 110 (9)e | 22 (20–40)e | 21 (0–43)e |
| 18 days | 107 (12)e | 109 (6)e | 14 (11–18)f | 62 (27–67)f |
| 30 days | 114 (29)e | 111 (32)e | 9 (4–22)e | 68 (61–100)f |
a VEGF and IL-8 cytoplasmic staining was evaluated by computer-assisted image analysis using 10 microscopic fields/tumor section at ×200 (0.033 mm2) and is expressed as the ratio of tumor expression to normal pancreatic epithelium expression multiplied by 100.
b The number of CD31-positive vessels was evaluated in 10 microscopic fields per tumor section at ×100 (0.159 mm2) using the Optimas 6.0 computer-assisted image analysis software.
c The percentage of TUNEL-positive endothelial cells was determined in 10 microscopic fields/tumor section at ×400 (0.011 mm2) by evaluating the ratio between the number of TUNEL-positive endothelial cells/field and the total number of endothelial cells/field.
d No significant difference compared with the control at the same time point.
e P < 0.05 compared with the control at the same time point.
f P < 0.002 compared with the control at the same time point.